Map Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 18 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.20 M
About Map Pharmaceuticals
Map Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 June 2006 and has a history of 18 years and seven months. Its registered office is in Distt Solan H P, Himachal Pradesh.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.20 M.
Ashish Kesari and Om Gupta serve as directors at the Company.
Company Details
-
LocationDistt Solan H P, Himachal Pradesh
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230HP2006PTC030350
-
Company No.
030350
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Jun 2006
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Map Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Kesari
|
Director | 15-Jun-2006 | Current |
|
Om Gupta
|
Director | 15-Jun-2006 | Current |
Financial Performance of Map Pharmaceuticals.
Map Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Map Pharmaceuticals?
In 2017, Map Pharmaceuticals had a promoter holding of 44.00% and a public holding of 56.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Gluck Biosciences Private LimitedAshish Kesari and Om Gupta are mutual person
Charges (Loans)
₹2.20 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.20 Cr
- Punjab National Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jan 2015 | Hdfc Bank Limited | ₹2.00 M | Open |
| 14 Dec 2012 | Punjab National Bank | ₹0.20 M | Open |
How Many Employees Work at Map Pharmaceuticals?
Unlock and access historical data on people associated with Map Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Map Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Map Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.